CRUK Cambridge Centre: Urological Malignancies
@CRUKCamUrol
Followers
460
Following
100
Media
58
Statuses
434
Cancer Research UK Cambridge Centre Urological Malignancies Virtual Institute. World class, interdisciplinary research to combat urological cancers.
Cambridge, UK
Joined July 2018
🚨 New blog: Our researchers publish new data demonstrating the prevalence of kidney cancer in high-risk individuals, using data from our @yorkshirecancer funded kidney screening trial. Read more 👉 https://t.co/CzKxaPfkMJ
cambridge-urologicalmalignancies.org.uk
In a European Urology Oncology paper, UM member Sabrina H Rossi and colleagues use data from the Yorkshire Kidney Screening Trial (YKST) and the Yorkshire Lung Screening Trial (YLST) to report the...
0
0
1
We've just shared the second blog in our series about the work of the International Neoadjuvant Kidney Cancer Consortium (INKCC), a group of experts building international strategy in research on neoadjuvant therapies for patients with kidney cancer: https://t.co/1IhMKpvEDB
cambridge-urologicalmalignancies.org.uk
In this second part of our blog series on the work of the International Neoadjuvant Kidney Cancer Consortium (INKCC) we consider how the group has found and built consensus, and how to proceed...
1
0
0
Congratulations to Harveer and Simon on publishing outcomes from their CANCAP study
A clinical trial led by members of our @CRUKCamUrol has revealed how a short course of targeted therapy prior to surgery can influence the biology of prostate cancer – even in men who do not carry known DNA repair gene mutations. Find out more ➡️ https://t.co/lMUeXQrPrN
0
0
4
Congratulations @Tom_J_Mitchell on winning the Christopher G Wood Rising Star Award at #IKCSEU2025 earlier this month - very well deserved!
1
2
10
Findings published in @EUplatinum suggest that the combined screening approach is feasible and of potential benefit: https://t.co/5Ac7pZeSvT (6/6)
0
0
0
When @YorkshireKST provided an additional upper abdominal CT scan for 4,019 people attending lung-cancer screening (funded by @yorkshirecancer), the study identified: 🚩10 new cases of kidney cancer 🔍10 other abdominal cancers 📈60 new abdominal aortic aneurisms. (5/6)
1
0
1
The analysis concludes that considering all relevant diseases in screening models is vital for developing cost-effective screening programmes. It also recommends a larger trial, which is currently in development by the UMVI with funding from @yorkshirecancer. (4/6)
1
0
0
The analysis considered detection of other conditions alongside kidney cancer, with the detection of abdominal aortic aneurysm the leading contributor to the cost-effectiveness of the screening programme. (3/6)
1
0
0
A paper, published in @BrJCancer, shows that adding an upper abdominal CT scan to the thoracic CT scan offered within the lung cancer screening programme has a 96% probability of being cost-effective: https://t.co/VZJVJMs4Hf (2/6)
1
0
0
New analysis by @SCHARRSheffield, in collaboration with UMVI researchers, using data from our world-first Yorkshire Kidney Screening Trial, shows that screening for kidney cancer is potentially cost effective. Read more: https://t.co/VZJVJMs4Hf (1/6)
1
1
0
Rebecca Wray, joint first author on this paper, presented her work at the @AACR Annual Meeting this weekend
New work led by James Jones, published this week in @NatureComms, has discovered early markers of response in patients treated for kidney cancer with venous tumour thrombus (VTT) using a drug called axitinib. https://t.co/0DZ0lP316U
0
0
3
Using a machine learning model to analyse data from the NAXIVA trial, @CRUKCamUrol members have discovered early markers of response in patients treated for kidney cancer with venous tumour thrombus using a drug called axitinib. @NatureComms Read more: https://t.co/EzNHjHlTWp
0
2
5
This work demonstrates how translational work is a vital part of clinical trials and shows the potential of AI and machine learning for finding relevant insights within huge datasets. Read more at our blog 👉 https://t.co/0DZ0lP316U
0
0
2
Joint first author and AI developer Rebecca Wray said that this translational work addresses a question ‘crucial’ to patient care – why some patients respond and others don’t.
1
0
2
Dr Jones and colleagues analysed blood and tumour samples from patients in NAXIVA, then used a machine learning model to unpick which factors were driving response in each patient. They found that placental growth factor levels in the blood can be used to predict response
1
0
1
In 2022, our NAXIVA trial, led by @grantissimus showed that 8 weeks of pre-surgery treatment with axitinib can reduce the extent of VTT in some patients with kidney cancer, making surgery safer. Dr Jones’s translational work offers an insight into why some patients respond.
1
0
1
New work led by James Jones, published this week in @NatureComms, has discovered early markers of response in patients treated for kidney cancer with venous tumour thrombus (VTT) using a drug called axitinib. https://t.co/0DZ0lP316U
1
0
3
Join us on Weds 23 April for breakfast and talks about future directions in kidney cancer research. Book your place: https://t.co/qqOymU0a4z
0
0
1
Fantastic to see Raghav Varma presenting at the National Ipsen RCC day on the important National Kidney Cancer Audit by @grantissimus et al on variations in kidney cancer care across the UK. Much work to do! @CRUKCamUrol @CUH_NHS @kidneycanceruk @CRUKCamCentre
0
2
5